Cisapride (compounded)

Cisapride is a potent prokinetic agent that enhances gastrointestinal motility through stimulation of serotonin 5-HT4 receptors located throughout the digestive tract. Originally marketed for human use under the brand name Propulsid, cisapride was withdrawn from the United States market in 2000 due to cardiac safety concerns in people, but it remains available through veterinary compounding pharmacies for use in horses and other animals. In equine medicine, cisapride has become a valuable tool for managing various motility disorders, particularly when other prokinetic agents have proven insufficient or are contraindicated.

The mechanism of action of cisapride involves selective activation of serotonin 5-HT4 receptors on enteric neurons within the gastrointestinal tract. This stimulation enhances the release of acetylcholine from myenteric plexus neurons, which in turn activates muscarinic receptors on smooth muscle cells to produce coordinated contractions. Unlike direct-acting cholinergic agonists, cisapride works through this indirect pathway to enhance physiological peristaltic patterns rather than causing uncoordinated muscle stimulation. The medication affects the entire gastrointestinal tract, promoting gastric emptying, small intestinal transit, and large intestinal motility, making it useful for conditions affecting various segments of the equine digestive system.

As cisapride is no longer commercially manufactured, all veterinary use requires compounded preparations obtained from licensed compounding pharmacies. These preparations are typically formulated as oral suspensions or tablets at concentrations suitable for equine dosing. The quality and consistency of compounded products can vary between pharmacies, making it important to obtain medication from reputable sources that follow appropriate quality control standards. Oral bioavailability of cisapride in horses is generally good, with effects typically observed within one to two hours of administration. The medication is usually given multiple times daily, with treatment duration depending on the underlying condition and clinical response.

The safety profile of cisapride in horses differs from the concerns that led to its removal from the human market. The cardiac effects that caused problems in humans, primarily prolongation of the QT interval leading to potentially fatal arrhythmias, appear to be much less significant in horses based on clinical experience. However, because systematic safety studies in horses are limited, veterinary supervision remains essential. The medication should be used judiciously, with attention to potential drug interactions that might increase cardiac risks. When used appropriately under veterinary guidance, cisapride represents an effective option for managing challenging equine motility disorders.

Post-operative ileus represents one of the primary indications for cisapride in equine practice. Following abdominal surgery for colic or other conditions, horses commonly experience a period of decreased or absent gastrointestinal motility that can significantly complicate recovery. This post-operative ileus may persist for days in some cases, leading to fluid accumulation in the stomach and intestines, abdominal distension, and risk of complications such as adhesion formation or gastric rupture. Cisapride's ability to stimulate coordinated motility throughout the digestive tract makes it valuable for hastening the return of normal gut function in surgical patients. It may be used alone or in combination with other prokinetic agents depending on the severity of the ileus.

Gastric emptying disorders constitute another important application for cisapride therapy in horses. Delayed gastric emptying can occur as a primary condition or secondary to various underlying diseases, including equine grass sickness, equine motor neuron disease, and certain forms of chronic intestinal dysfunction. Affected horses may exhibit decreased appetite, post-prandial discomfort, excessive salivation, and in severe cases, development of gastric impaction or rupture. Cisapride enhances the coordinated contractions necessary to propel ingesta from the stomach into the duodenum, improving clinical signs and reducing the risk of serious complications. Long-term therapy may be necessary for horses with chronic gastric emptying dysfunction.

Chronic intestinal pseudo-obstruction, a condition characterized by clinical signs of intestinal obstruction without mechanical blockage, may respond to cisapride therapy. This syndrome can affect various segments of the intestinal tract and may be related to abnormalities in enteric nervous system function. Horses with pseudo-obstruction experience recurrent episodes of colic, abdominal distension, and altered manure production despite the absence of identifiable physical obstruction. By enhancing enteric nervous system function through 5-HT4 receptor stimulation, cisapride can improve intestinal coordination and reduce the frequency and severity of clinical episodes in some affected horses.

Recovery from large colon impactions and other non-surgical causes of decreased motility represents an additional application for cisapride. Following resolution of an impaction through medical management with intravenous fluids and laxatives, ongoing support of motility can help prevent recurrence and support complete recovery. Similarly, horses recovering from other conditions that have affected gut motility, such as prolonged anesthesia for non-abdominal surgeries or extended periods of limited feed intake, may benefit from short-term prokinetic support to reestablish normal digestive patterns.

Veterinarians select cisapride based on several factors including the specific nature of the motility disorder, previous response to other prokinetics, potential for drug interactions, and practical considerations such as ease of administration. Cisapride's oral formulation makes it suitable for outpatient management of chronic conditions where injectable medications would be impractical. Its mechanism of action through serotonin receptors provides an alternative pathway for patients who have not responded adequately to cholinergic or dopaminergic prokinetics, or who have contraindications to those drug classes.

Cisapride dosing in horses must be determined by the attending veterinarian based on individual patient assessment, the condition being treated, and consideration of any concurrent medications or health issues. The compounded nature of available preparations adds complexity, as concentration and formulation may vary between pharmacies, requiring careful attention to product-specific dosing instructions. Accurate weight determination remains essential, with recognition that horses range from miniatures under three hundred pounds to draft breeds exceeding two thousand pounds. Using weight tapes provides reasonable estimates for most horses, though scales offer greater precision when available.

Typical dosing ranges for cisapride in horses fall between 0.1 to 0.2 milligrams per kilogram of body weight administered orally. Some protocols use higher doses up to 0.5 milligrams per kilogram for refractory cases, though higher doses may increase the risk of adverse effects. The frequency of administration is typically every eight to twelve hours, with most protocols calling for three times daily dosing during acute treatment phases. Loading doses are not typically used with cisapride, and steady therapeutic levels are achieved through consistent regular dosing. The veterinarian will specify the exact dose, frequency, and duration appropriate for each case.

Treatment duration with cisapride varies considerably depending on the underlying condition. For acute post-operative ileus, treatment typically continues until clear evidence of return of normal gastrointestinal function is observed, usually indicated by passage of manure, reduced nasogastric reflux, and return of normal borborygmi. This may require several days to over a week of therapy in some cases. For chronic conditions such as delayed gastric emptying or intestinal pseudo-obstruction, longer-term maintenance therapy may be necessary. Some horses require ongoing treatment for extended periods, while others may be gradually weaned off medication once underlying factors are addressed.

Oral administration of compounded cisapride preparations requires attention to proper technique and timing. Oral suspensions should be shaken thoroughly before each dose to ensure uniform drug distribution. The medication can be administered directly into the horse's mouth using an oral dosing syringe, positioning the syringe to deposit the medication on the back of the tongue to encourage swallowing. Compounded tablets may be given directly or crushed and mixed with a small amount of palatable feed, though giving with feed may affect absorption rates. Timing relative to meals may influence drug effect, and specific instructions from the veterinarian should be followed consistently.

Missed doses should be handled according to veterinary guidance, but general principles apply. If a dose is missed and discovered within a few hours, it may typically be given at that time. However, if the next scheduled dose is approaching, skipping the missed dose rather than doubling up is usually advisable. Double dosing can increase the risk of adverse effects without providing additional therapeutic benefit. Maintaining a consistent dosing schedule optimizes therapeutic outcomes, so setting reminders or alarms may help prevent missed doses during treatment periods.

Completing the prescribed course of cisapride treatment is important for optimal outcomes. For acute conditions, discontinuing treatment prematurely may allow recurrence of motility dysfunction before the underlying condition has fully resolved. For chronic conditions, sudden discontinuation may lead to abrupt return of clinical signs. The veterinarian will provide guidance on when and how to discontinue therapy, which may involve gradual tapering in some cases. If concerns arise about the horse's response to treatment or if adverse effects develop, consulting the veterinarian before making dosing changes is essential.

Cisapride is generally well-tolerated in horses at standard therapeutic doses, with most treated horses experiencing no significant adverse effects during appropriate short-term therapy. The side effect profile in horses appears more favorable than that observed in humans, where cardiac concerns led to market withdrawal. However, the relatively limited systematic study of cisapride in horses means that monitoring during treatment remains prudent. Understanding potential adverse effects allows caregivers to identify problems promptly and seek appropriate veterinary attention when necessary.

Common and typically mild side effects of cisapride in horses include soft feces or mild diarrhea, reflecting the medication's intended effect of enhancing intestinal motility. Some horses may exhibit increased frequency of defecation as transit time through the intestinal tract decreases. Transient increases in borborygmi may be noted as gut sounds become more active. Mild abdominal discomfort or changes in appetite are occasionally observed during initial treatment. These effects are usually self-limiting and may represent evidence that the medication is producing its intended pharmacological effect rather than true adverse reactions.

Moderate side effects that warrant closer monitoring include persistent diarrhea that does not stabilize or worsens over time, which could lead to dehydration and electrolyte imbalances if not addressed. More pronounced abdominal discomfort or signs of mild colic should prompt veterinary consultation, as this could indicate excessive gut stimulation or emergence of a complication. Changes in behavior, including restlessness or signs of anxiety, are occasionally reported. Any signs suggesting cardiac abnormalities, such as irregular heart rhythm, weakness, or exercise intolerance, should be taken seriously given the cardiac concerns associated with cisapride in other species.

Serious side effects requiring immediate veterinary attention are rare with cisapride in horses but must be recognized. Severe or bloody diarrhea could indicate significant intestinal disturbance requiring intervention. Signs of acute colic with severe abdominal pain demand immediate assessment to rule out complications. Cardiac arrhythmias, while uncommon in horses at therapeutic doses, represent a serious concern given the drug's known effects on cardiac potassium channels in other species. Collapse, profound weakness, or signs of cardiovascular compromise require emergency veterinary care. Allergic reactions, though rare, may manifest as hives, facial swelling, or respiratory distress.

Long-term use considerations and rare side effects have not been extensively characterized in horses due to limited longitudinal studies. The potential for cumulative effects with extended therapy is unknown, and horses on long-term cisapride for chronic conditions should receive periodic veterinary reassessment. The quality of compounded preparations may vary, and inconsistencies between batches could theoretically contribute to variable responses. If a horse experiences unexpected changes in response to medication, including apparent loss of efficacy or emergence of new side effects, this should be reported to the veterinarian. Severe adverse effects should prompt immediate discontinuation of the medication pending veterinary evaluation.

Cisapride is contraindicated in horses with known hypersensitivity to the medication or any components of the compounded formulation. Previous allergic reactions or adverse responses to cisapride should preclude future use. Because compounded preparations may contain various inactive ingredients depending on the pharmacy, horses with known sensitivities to common pharmaceutical additives such as certain flavoring agents or preservatives may require specially formulated preparations or alternative medications. Any history of severe adverse reactions to other prokinetic medications should be disclosed to the veterinarian when considering cisapride therapy.

Horses with cardiac arrhythmias or known cardiac conduction abnormalities should not receive cisapride due to the medication's potential effects on cardiac repolarization. The drug is known to prolong the QT interval, which can predispose to dangerous ventricular arrhythmias in susceptible individuals. While this effect appears less pronounced in horses than in humans, horses with pre-existing cardiac conditions may be at increased risk. Horses should ideally undergo cardiac assessment before initiating cisapride therapy if any concerns about cardiac health exist. Additionally, concurrent use of other medications known to prolong the QT interval or inhibit cisapride metabolism can increase cardiac risks and may represent relative or absolute contraindications.

Gastrointestinal obstruction or suspected mechanical blockage of the digestive tract constitutes an absolute contraindication to cisapride, as with other prokinetic agents. Stimulating intestinal contractions against an obstruction can lead to intestinal rupture, peritonitis, and death. The veterinarian must rule out obstructive causes of decreased motility before initiating prokinetic therapy. Similarly, conditions involving active gastrointestinal hemorrhage or perforation preclude cisapride use, as enhanced motility could worsen bleeding or spread contamination. Recent gastrointestinal surgery may also contraindicate use depending on the nature and location of the procedure.

Special considerations apply to pregnant mares, nursing mares, and young foals, where safety data for cisapride is limited to absent. The effects of cisapride on fetal development have not been adequately studied in horses, and the medication should be avoided during pregnancy unless no safer alternatives exist and the benefit clearly outweighs potential risks. Whether cisapride passes into mare's milk and could affect nursing foals is unknown. Very young foals may have immature drug-metabolizing capacity and could show altered responses to the medication. Geriatric horses with concurrent health conditions, particularly cardiac disease, require careful individual assessment. Horses with significant liver disease may have impaired metabolism of cisapride, potentially leading to drug accumulation and increased risk of adverse effects.

The most clinically significant drug interactions involving cisapride relate to medications that inhibit its hepatic metabolism through the cytochrome P450 3A4 enzyme system. When cisapride metabolism is inhibited, plasma concentrations can rise to levels that increase the risk of cardiac adverse effects, particularly QT interval prolongation and ventricular arrhythmias. Medications known to strongly inhibit CYP3A4 and that should be avoided or used with extreme caution with cisapride include certain azole antifungal agents such as ketoconazole, itraconazole, and fluconazole, as well as macrolide antibiotics including erythromycin and clarithromycin. Notably, erythromycin is sometimes used in horses as a prokinetic agent itself, and combining it with cisapride would be inappropriate.

Medications that independently prolong the QT interval can have additive effects with cisapride, increasing the risk of cardiac arrhythmias. While many of these drugs are used primarily in human medicine, some may be encountered in equine practice. Certain antimicrobials, antiarrhythmic drugs, and other medications can affect cardiac repolarization. The veterinarian will consider the complete medication profile when prescribing cisapride to identify potential interactions. Even medications that individually have minimal cardiac effects may contribute to risk when multiple agents with similar properties are combined.

Cisapride may interact with other gastrointestinal medications in ways that affect its efficacy or the efficacy of the other agents. Anticholinergic medications that slow gastrointestinal motility would be expected to antagonize the effects of cisapride, potentially resulting in therapeutic failure. Antacids or acid-suppressing medications may affect cisapride absorption if given concurrently, though this interaction is generally manageable with appropriate timing of administration. Conversely, combining cisapride with other prokinetic agents that work through different mechanisms may produce additive or synergistic effects on motility, which could be therapeutically useful but also increases the risk of excessive gut stimulation.

Competition drug considerations for horses receiving cisapride require careful attention. Cisapride would be considered a prohibited substance under most competition rules due to its pharmacological effects on the gastrointestinal system. Detection times in horses have not been extensively characterized, making it difficult to establish safe withdrawal periods with certainty. For horses that compete, owners should consult with their veterinarian and verify current regulations from relevant governing bodies such as FEI, USEF, or breed associations. Treatment records should be maintained meticulously. In many cases, horses being treated with cisapride for legitimate medical conditions should be withdrawn from competition until well after treatment has concluded. The interaction between cisapride and other medications commonly used in performance horses adds complexity to these considerations.

Monitoring during cisapride therapy should include regular assessment of gastrointestinal function to evaluate therapeutic response. This includes monitoring frequency and consistency of manure production, appetite and feed intake, presence and character of borborygmi, and any signs of abdominal discomfort. For hospitalized horses with nasogastric tubes in place, reflux volume provides important information about gastric emptying function. Cardiovascular monitoring is advisable, particularly for horses receiving higher doses, those on prolonged therapy, or those with any pre-existing cardiac conditions. Baseline and periodic electrocardiograms may be warranted in some cases to monitor for QT interval changes, though this is not routinely performed in most clinical situations.

Special populations requiring additional consideration include foals, where limited data exists regarding appropriate dosing and safety. Young horses may have immature hepatic enzyme systems affecting drug metabolism and potentially different sensitivity to the medication's effects. Dose adjustments may be necessary, and close monitoring is essential when treating foals with cisapride. Geriatric horses often have concurrent health conditions that may affect candidacy for cisapride therapy, and hepatic or cardiac function may be compromised with age. Pregnant mares should generally avoid cisapride unless absolutely necessary due to unknown effects on fetal development. Lactating mares present concerns about potential exposure of nursing foals through milk.

Competition and performance horses face significant regulatory considerations with cisapride use. The medication is classified as prohibited under FEI rules and most domestic competition regulations. Detection times have not been well established in horses, making it extremely difficult to predict when treated horses would test negative. Performance horses receiving cisapride for legitimate therapeutic reasons should not be expected to compete until an extended period after treatment has concluded. Owners should communicate openly with their veterinarians and potentially with competition officials about any treatments their horses have received. Detailed medication records documenting dates of treatment, doses administered, and indication for therapy should be maintained.

Administration and handling precautions for compounded cisapride preparations include verifying that the product comes from a reputable compounding pharmacy with appropriate quality control measures. Compounded medications should be stored according to the pharmacy's instructions, typically at room temperature or refrigerated depending on the formulation. Expiration dates assigned by the compounding pharmacy should be observed. Personnel handling the medication should use reasonable precautions to minimize exposure, though cisapride does not pose extreme handling hazards under normal circumstances.

Long-term therapy considerations include the need for periodic reassessment of whether continued treatment remains necessary and appropriate. The underlying condition prompting cisapride use should be re-evaluated over time to determine if resolution has occurred or if alternative management strategies have become viable. Extended treatment carries ongoing exposure to potential adverse effects and ongoing cost considerations. For horses on maintenance cisapride for chronic conditions, periodic veterinary examinations help ensure the medication continues to provide benefit without causing harm. Alternative or complementary management approaches, including dietary modifications and exercise programs, should be explored as part of comprehensive case management.

Storage requirements for compounded cisapride preparations vary depending on the specific formulation and should follow the instructions provided by the compounding pharmacy. Many oral suspensions require refrigeration to maintain stability, typically between thirty-six and forty-six degrees Fahrenheit. Freezing should be avoided as it may affect medication consistency and stability. Compounded tablets may be stable at room temperature but should be protected from excessive heat, moisture, and light. Keeping medication in the original container with secure closure helps protect against environmental degradation. In barn settings, medications requiring refrigeration should be stored in dedicated refrigerators away from food items, and temperature should be monitored to ensure appropriate conditions are maintained.

Handling compounded cisapride requires standard pharmaceutical precautions without unusual safety concerns. Hands should be washed before and after handling medication. Oral syringes used for administration should be rinsed after use and dedicated to the individual horse to prevent cross-contamination. Gloves may be worn when handling liquid preparations if desired, though this is not strictly required. Spills of liquid medication should be cleaned promptly with soap and water. The medication should be kept out of reach of children, household pets, and horses other than those being treated. Accidental ingestion by humans would warrant contact with a poison control center or healthcare provider, though serious toxicity from small exposures is unlikely.

Expiration dates on compounded preparations must be observed carefully. Unlike commercially manufactured medications with extensive stability data, compounded products typically have shorter beyond-use dates assigned based on general stability guidelines rather than product-specific testing. Using medication beyond its expiration date risks reduced potency and potential degradation into less effective or potentially harmful compounds. Disposal of expired or unused cisapride should follow appropriate guidelines for pharmaceutical waste. The medication should not be discarded in regular trash or flushed into sewer systems. Veterinary clinics, pharmacies, or community hazardous waste programs may accept expired medications for proper disposal. Consultation with the dispensing pharmacy regarding appropriate disposal methods is advisable.

Draft horse breeds require careful attention to cisapride dosing due to their significantly larger body mass compared to light horse breeds. Accurate weight determination becomes particularly important when dealing with horses that may weigh eighteen hundred to twenty-two hundred pounds or more. Weight estimation using tapes or scales helps ensure appropriate dosing, as underdosing may result in therapeutic failure while overdosing increases risks. The metabolic differences between draft and light horse breeds have not been specifically studied with respect to cisapride, but may potentially affect drug distribution and elimination. Draft breeds may be predisposed to certain types of colic and intestinal conditions that bring them to treatment with prokinetic agents.

Light horse breeds and warmbloods represent the populations where most clinical experience with cisapride has been accumulated, and standard dosing protocols typically apply. Individual variation always exists, and therapeutic responses should be monitored in each patient. Performance horses in these categories face particular considerations regarding competition drug testing and withdrawal times. Thoroughbreds and Standardbreds may encounter cisapride use following surgeries or during treatment of gastrointestinal conditions that could affect racing careers. Quarter Horses and related breeds may have genetic conditions such as HYPP or PSSM that affect overall health and potentially influence medication selection or monitoring, though these conditions do not specifically interact with cisapride.

Ponies and miniature horses require precise dosing due to their smaller body size. The concentration of compounded cisapride preparations may make accurate measurement of small doses challenging, and consultation with the compounding pharmacy about appropriate formulation strength may be helpful. Ponies and miniature horses are predisposed to metabolic conditions and laminitis risk, which while not direct contraindications to cisapride, represent important aspects of overall patient assessment. Gastrointestinal conditions in small equines may have different characteristics than in full-sized horses, affecting treatment decisions.

Breed-specific genetic conditions can influence overall case management when cisapride is part of the treatment plan. Friesians have higher rates of megaesophagus and esophageal disorders that may require prokinetic support, making cisapride a relevant medication in this breed. The Friesian predisposition to aortic rupture warrants attention to cardiovascular status when using any medication with potential cardiac effects. Arabians may have higher incidence of certain cardiac conditions requiring baseline assessment. Individual patient evaluation remains essential regardless of breed background, as breed predispositions represent population tendencies rather than guarantees for any individual horse. The veterinarian will incorporate breed considerations into the overall treatment plan.

Within the prokinetic drug class, several alternatives to cisapride are available for equine use, each with distinct mechanisms and clinical considerations. Metoclopramide works primarily through dopamine D2 receptor antagonism with additional effects on serotonin receptors, enhancing gastric emptying and upper gastrointestinal motility. It offers the advantage of being commercially available rather than requiring compounding but has a narrower spectrum of effect concentrated on the proximal gut. Bethanechol is a direct-acting cholinergic agonist that stimulates muscarinic receptors throughout the gastrointestinal tract, producing effects through a different pathway than cisapride. Lidocaine administered as a constant-rate intravenous infusion has prokinetic properties and is frequently used in hospitalized horses with post-operative ileus, though its mechanism of action is not fully understood. Erythromycin at low doses acts as a motilin receptor agonist with prokinetic effects, though its use is complicated by potential for promoting antimicrobial resistance.

Different classes of medications may be appropriate depending on the underlying cause of the motility disorder being treated. When inflammation contributes to ileus, anti-inflammatory therapy targeting the primary condition may help restore motility. Pain management with appropriate analgesics supports patient comfort while avoiding agents that excessively suppress gut function. For horses with suspected bacterial complications, antimicrobial therapy may be indicated. Fluid therapy and electrolyte correction support normal gut function and are essential components of managing many conditions that require prokinetic support. The veterinarian will determine the most appropriate combination of therapies based on comprehensive patient assessment.

Complementary approaches and supportive care measures work alongside pharmacological prokinetic therapy to optimize outcomes. Hand-walking hospitalized horses when their condition permits provides gentle exercise that can help stimulate gut motility naturally. Dietary management during recovery from motility disorders typically involves gradual reintroduction of feed, starting with small amounts of high-quality grass hay before advancing to normal rations. Addressing stress and environmental factors that may contribute to gastrointestinal dysfunction can support long-term management. For horses with chronic motility issues, management modifications such as multiple small meals, adequate turnout and exercise, and minimizing stressors may reduce medication requirements. Any medication substitutions or additions should be made only under veterinary guidance to ensure safety and appropriate therapy.